Novartis is budgeting $6B a year for bolt-ons

Novartis ($NVS) CEO Joe Jimenez says the pharma giant easily has enough cash on hand to keep the dividends flowing to investors while reserving up to $6 billion for new bolt-on buyouts. In an interview with the Swiss newspaper Schweiz am Sonntag, which was picked up by Reuters, Jimenez says that the sweet spot for deals lies in the $2 billion to $4 billion arena--modest for a company of that size. Most of the Big Pharma companies like Roche ($RHHBY) and AstraZeneca ($AZN) will probably top out around $10 billion on buyout deals, analysts note, putting them in the same ballpark as Amgen ($AMGN) when it acquired Onyx ($ONXX) in one of the biggest biotech deals of the year. Of course, these numbers have a habit of shifting. Novartis Chairman Joerg Reinhardt told reporters earlier this year that a $10 billion buyout was "not out of reach." The big $20 billion-plus pacts seem in distinct disfavor these days, with the major M&A tie-ups between pharma rivals looking like a relic of a bygone era. Report

Suggested Articles

When thinking about clinical research patient recruitment, a crucial step is building effective patient recruitment advertising campaigns.

Novavax delayed the start of a large phase 3 trial for its COVID-19 vaccine in the U.S. and Mexico, thanks to delays in scaling up manufacturing.

The decision to dump IL33r antagonist GSK3772847 follows lackluster clinical data on rival candidates against the same target.